Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06917131 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Royal Jelly as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Systemic Arterial Hypertension

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Aug 31, 2025 to Dec 10, 2026v2 Show 5 more changesShow less
    • Primary endpoint revised
    • Study completion date: Dec 20, 2025 to Dec 10, 2026
    • Eligibility criteria shortened, about 49 words
    • Secondary endpoints expanded, about 27 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study aims to evaluate the effect of the royal jelly on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.
Trial Details
NCT Number NCT06917131
Lead Sponsor Universidade Federal Fluminense
Conditions
(from sponsor)		 Hypertension, Cardiovascular Diseases (CVD), Inflammation
Related terms Cardiovascular Diseases, Hypertension, Inflammation
Enrollment 34 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov